IIL launches pediatric dose of India’s 1st Indigenous Hepatitis A vaccine

New Delhi: Indian Immunologicals Limited (IIL) has launched a pediatric dose of India’s first indigenous Hepatitis A vaccine, Havisure (0.5 ml), marking a milestone in the company’s mission to provide accessible and effective vaccines.

The new pediatric dose of Havisure represents a major step forward in combating Hepatitis A, a highly contagious liver infection that predominantly affects children and can lead to severe health complications. Vaccination remains the most effective and cost-efficient method for preventing this disease.

Dr. K. Anand Kumar, Managing Director of Indian Immunologicals Limited, expressed, “We are delighted to introduce the pediatric dose of Havisure, the first indigenously developed Hepatitis A vaccine in India. IIL is the single largest contributor to the self-sufficiency of vaccines in the country, this launch is a testament to IIL’s unwavering dedication to innovation and public health. As we celebrate Teachers’ Day, we are reminded of shaping a brighter future for children. We are confident that this vaccine will contribute to a brighter and healthier future for our younger generation. IIL’s endeavor to make Indigenous vaccines will give the necessary impetus to “Make in India” efforts.”

To celebrate the launch and promote public health, IIL organized several community-focused activities. These included free Hepatitis A vaccination drives for children at two Hyderabad orphanages, including one for blind children, and a health awareness session at an old age home. These initiatives reflect IIL’s ongoing efforts to raise health awareness and support community well-being.

 IIL remains the only company in India to develop an indigenous Hepatitis A vaccine, which is available in both pediatric (0.5 ml) and adult (1 ml) doses.